Skip to main content
Full access
Letter to the Editor
Published Online: 1 June 2000

Acute Onset of Auditory Hallucinations After Initiation of Celecoxib Therapy

Celecoxib is a nonsteroidal anti-inflammatory agent that is selective for cyclooxygenase-2. This selectivity offers the ability to control inflammation and pain without some of the side effects of traditional nonsteroidal anti-inflammatory drug therapy, particularly gastrointestinal bleeding (1). The multiple side effects of traditional nonsteroidal anti-inflammatory drugs are well described; they include psychiatric manifestations such as psychosis, delirium, agitation, and depression (25). We report a case in which a patient developed overt auditory hallucinations after treatment with celecoxib.
Ms. A, a 78-year-old woman, reported a progressive onset of auditory hallucinations within 10 days of initiating celecoxib therapy, 200 mg b.i.d., for osteoarthritis pain. She reported initially hearing thumping sounds within the first 2 days of therapy, and they progressively increased to the sound of voices calling her name and repeating words from the television and radio. She underwent evaluation by an internist and consulted an otolaryngologist with negative results. She was seen for psychiatric evaluation because of fears that she was “going crazy.” Ms. A’s concurrent medications included 20 mg/day of quinapril, 240 mg/day of sustained-release verapamil for hypertension, 20 mg b.i.d. of isosorbide dinitrate for angina, 20 mg/day of tamoxifen due to a history of breast cancer, and 500 mg t.i.d. of calcium carbonate for osteoporosis. There had been no changes in her concurrent medication regimen over the past year until the addition of celecoxib.
Ms. A was alert and mildly anxious, with a clear sensorium and intact cognition. She described vivid hallucinations and stated that voices were calling her name and repeating the words of radio and television announcers. She was advised to discontinue the celecoxib; she then reported gradual improvement over the next 3 days. By the 4th day her symptoms disappeared, but she reported increasing pain and was advised by her internist to resume taking the celecoxib at a lower dose—100 mg b.i.d. daily. After 5 days, Ms. A again began hearing voices calling her name and repeating phrases from the television. She was again advised to discontinue the celecoxib, and her symptoms rapidly improved. Because of multiple gastrointestinal side effects from other nonsteroidal anti-inflammatory agents, she resumed taking celecoxib, 100 mg/day, on an as-needed basis. She reports hearing occasional thumping noises but feels able to tolerate them.
Cyclooxygenase-2 is present in brain tissue (1). The potential exists for psychiatric side effects with drugs selective for this enzyme. This patient developed hallucinations that were clearly associated with the initiation of celecoxib therapy and recurred with retreatment. Despite the significant advantages of celecoxib over traditional nonselective nonsteroidal anti-inflammatory drugs in their lack of effects on the gastric mucosa and platelets (1), practitioners must be aware of potential adverse psychiatric events with the use of celecoxib.

References

1.
Hawkey CJ: COX-2 inhibitors. Lancet 1999; 353:307–314
2.
Browning CH: Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med 1996; 26:25–34
3.
Hoppmann RA, Peden JG, Ober SK: Central nervous system side effects of nonsteroidal anti-inflammatory drugs: aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151:1309–1313
4.
Griffith JD, Smith CH, Smith RC: Paranoid psychosis in a patient receiving ibuprofen, a prostaglandin synthesis inhibitor: case report. J Clin Psychiatry 1982; 43:499–500
5.
Tollefson GD, Garvey MJ: Indomethacin and prostaglandins: their behavioral relationships in an acute toxic psychosis. J Clin Psychopharmacol 1982; 2:62–64

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1022-a - 1023

History

Published online: 1 June 2000
Published in print: June 2000

Authors

Affiliations

MELINDA S. LANTZ, M.D.
VINCENT GIAMBANCO, R.PH.
New York, N.Y.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share